Company profile
ITBMed company profile
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
Business identity
- Website
- http://itb-med.com/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2015-01-01, Year
Headquarters
- Headquarters
- Artëm, Primorye, Russia
- Postal code
- 111 53
- Country code
- RU
- Continent
- Europe